Vertex Pharmaceuticals Incorporated Company Profile (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "VRTX."

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its quarterly earnings results on Thursday, April, 27th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.04 by $0.09. The company earned $714.72 million during the quarter, compared to analysts' expectations of $692.64 million. Vertex Pharmaceuticals Incorporated had a net margin of 34.92% and a return on equity of 74.81%. The business's quarterly revenue was up 79.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.09 earnings per share. View Vertex Pharmaceuticals Incorporated's Earnings History.

Vertex Pharmaceuticals Incorporated is scheduled to release their next quarterly earnings announcement on Tuesday, July, 25th 2017. View Earnings Estimates for Vertex Pharmaceuticals Incorporated.

24 equities research analysts have issued 1-year target prices for Vertex Pharmaceuticals Incorporated's shares. Their predictions range from $75.00 to $155.00. On average, they anticipate Vertex Pharmaceuticals Incorporated's share price to reach $118.25 in the next twelve months. View Analyst Ratings for Vertex Pharmaceuticals Incorporated.

Here are some recent quotes from research analysts about Vertex Pharmaceuticals Incorporated stock:

• 1. Needham & Company LLC analysts commented, "Vertex announced 1Q17 financial results last night. Orkambi WW sales $295M beat our $277.5M and consensus $280M ests. Kalydeco WW sales $186M beat our $178.0M and consensus $175M ests. Mgmt raised Kalydeco, but left unch Orkambi guidance ($1.1-1.3B Orkambi and $710M-$730M from $690-710M Kalydeco). Orkambi driven by strong uptake and compliance in pediatric pts and Kalydeco driven by one time reimbursement in Europe. Our 2Q17 Orkambi and Kalydeco ests are $294.0M (was $287.5M) and $179.0M (was $178.0M). Stock reflects IVA/ TEZ commercial success and we maintain HOLD." (4/28/2017)
• 2. Maxim Group analysts commented, "Vertex reported 1Q17 with total CF revenue of $481M, which was above consensus of $444M, driven by both Orkambi and Kalydeco revenues beating estimates." (4/28/2017)
• 3. According to Zacks Investment Research, "Vertex has two cystic fibrosis (CF) CF drugs – Kalydeco & Orkambi – in its portfolio with blockbuster potential. However, Vertex has faced many challenges with respect to commercialization of Orkambi in ex-U.S. markets. We believe the 2017 Orkambi revenue guidance is below expectations and dependent on reimbursement discussions in Europe. However, Vertex’s CF pipeline is quite strong.  Investor focus will now be on the triple combination CF regimens which are crucial for long-term growth at Vertex. Although the stock declined in 2016, it has done well this year.  Recently, positive data from two late-stage trials evaluating a combination of tezacaftor and Kalydeco pushed up the shares. Estimates have also gone up lately ahead of the company’s Q1 earnings release. The company has a mixed record of earnings surprises in recent quarters. " (4/12/2017)
• 4. BMO Capital Markets analysts commented, "We believe Vertex's acquisition of Concert's CTP-656, a deuterated ivacaftor (Kalydeco), removes a key potential competitor in the cystic fibrosis space. In addition, CTP-656 could replace Kalydeco in the triple combo, allowing a once-daily (QD) regimen, which would offset an important advaVertex Pharma (NASDAQ: VRTX)ntage of Galapagos's QD triple combo in development. We also believe CTP-656's later patent expiration date (2032 vs. 2027 for Kalydeco) will be an important lifecycle management component of Vertex's cystic fibrosis franchise." (3/7/2017)
• 5. Robert W. Baird analysts commented, "Vertex announced plans to acquire Concert Pharmaceuticals' CTP-656, or deuterated ivacaftor. We think this acquisition highlights Vertex's commitment to defending its position as the leading CF company as it both eliminates a potential competitor and allows access to a once-daily modified version of ivacaftor with a longer patent life than ivacaftor itself. Overall, we think this is a smart deal for the company at a reasonable price, and reiterate our Outperform rating." (3/6/2017)

Some companies that are related to Vertex Pharmaceuticals Incorporated include Regeneron Pharmaceuticals (REGN), TESARO (TSRO), Exelixis (EXEL), BIOVERATIV INC (BIVV), Kite Pharma (KITE), bluebird bio (BLUE), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Agios Pharmaceuticals (AGIO), GW Pharmaceuticals PLC (GWPH), Axovant Sciences (AXON), Prothena Corporation PLC (PRTA), AveXis (AVXS), Halozyme Therapeutics (HALO), Loxo Oncology (LOXO), Radius Health (RDUS) and Sarepta Therapeutics (SRPT).

Vertex Pharmaceuticals Incorporated's management team includes the folowing people:

• Jeffrey M. Leiden M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer
• Ian F. Smith CPA, Chief Financial Officer, Chief Operating Officer, Executive Vice President
• Michael J. Parini J.D., Executive Vice President, Chief Legal and Administrative Officer
• David Altshuler M.D., Ph.D., Executive Vice President - Global Research, Chief Scientific Officer
• Stuart A. Arbuckle, Executive Vice President, Chief Commercial Officer
• Jeffrey A. Chodakewitz M.D., Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
• Amit K. Sachdev J.D., Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
• Paul M. Silva, Senior Vice President, Corporate Controller
• Bruce I. Sachs, Lead Director, Independent Director
• Elaine S. Ullian, Co-Lead Independent Director

Vertex Pharmaceuticals Incorporated's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.73%), FMR LLC (7.57%), Vanguard Group Inc. (6.61%), State Street Corp (4.82%), Clearbridge Investments LLC (3.51%) and Ameriprise Financial Inc. (3.31%). Company insiders that own Vertex Pharmaceuticals Incorporated stock include Amit Sachdev, David Altshuler, Elaine Ullian, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee. View Institutional Ownership Trends for Vertex Pharmaceuticals Incorporated.

Vertex Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Asset Management Americas Inc., Thrivent Financial For Lutherans, Point72 Asset Management L.P., Ameriprise Financial Inc., Manning & Napier Advisors LLC, AXA and Lazard Asset Management LLC. Company insiders that have sold Vertex Pharmaceuticals Incorporated stock in the last year include Amit Sachdev, David Altshuler, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Paul M Silva, Sangeeta N Bhatia and Stuart A Arbuckle. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.

Vertex Pharmaceuticals Incorporated's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Westfield Capital Management Co. LP, Morgan Stanley, TIAA CREF Investment Management LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.

Shares of Vertex Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Vertex Pharmaceuticals Incorporated stock can currently be purchased for approximately $133.50.